CompletedNCT02108028
Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults With Cancer
Studying Chronic granulomatous disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Lori S Wiener, Ph.D.National Cancer Institute (NCI)
- Enrollment
- 272 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2024
Study locations (9)
- Children's Hospital of Orange County, Orange, California, United States
- Childrens National Medical Center, Washington D.C., District of Columbia, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- The Johns Hopkins Hospital, Baltimore, Maryland, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Children's Hospital at Montefiore, The Bronx, New York, United States
- Rhode Island Hospital (Lifespan), Providence, Rhode Island, United States
- Cook Childrens Hospital, Fort Worth, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02108028 on ClinicalTrials.govOther trials for Chronic granulomatous disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07284641Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)Paul Szabolcs
- ENROLLING BY INVITATIONPHASE1NCT07113743Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous DiseaseNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE1, PHASE2NCT06876363Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous DiseaseEnsoma
- RECRUITINGNCT06605378Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous DiseaseEnsoma
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT06559176A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )Prime Medicine, Inc.
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT06253507pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)National Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE1NCT06325709Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous DiseaseNational Institute of Allergy and Infectious Diseases (NIAID)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT05600907Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)National Institute of Allergy and Infectious Diseases (NIAID)